Publications by authors named "Robin Eisenburger"

Melanoma causes the majority of skin cancer-related deaths. Despite novel therapy options, metastatic melanoma still has a poor prognosis. Immune checkpoint inhibition (ICI) therapy has been shown to prolong overall survival in patients with advanced melanoma, but mucosal melanomas respond less favorably compared to melanomas of cutaneous origin.

View Article and Find Full Text PDF

The interdisciplinary treatment of skin cancer in the head and neck area requires close collaboration between different specialist disciplines. The most common non-melanoma skin cancer tumor entities are cutaneous squamous cell carcinoma and basal cell carcinoma as well as their precursor lesions. One of the less common tumors is Merkel cell carcinoma, which also occurs primarily in light-exposed areas and, in contrast to squamous and basal cell carcinoma, is more likely to metastasize.

View Article and Find Full Text PDF
Article Synopsis
  • The study highlights that dermatologists in Germany face challenges in diagnosing skin conditions in people of color (PoC), which can lead to misdiagnoses.* -
  • An online survey of 129 dermatologists showed they performed better at identifying skin diseases in light skin (Ls) patients compared to patients with skin of color (SoC), correctly diagnosing 72.1% vs. 52.8% of cases.* -
  • The results indicate a need for additional training for dermatologists to enhance their visual diagnostic skills and confidence when treating patients with SoC.*
View Article and Find Full Text PDF

Metastatic melanoma is a complex and deadly disease. Due to its complexity, the development of novel therapeutic strategies to inhibit metastatic melanoma remains an outstanding challenge. Our ability to study metastasis is advanced with the development of in vitro and in vivo models that better mimic the different steps of the metastatic cascade beginning from primary tumor initiation to final metastatic seeding.

View Article and Find Full Text PDF

Purpose: The MUNICH Preterm and Term Clinical (MUNICH-PreTCl) birth cohort was established to uncover pathological processes contributing to infant/childhood morbidity and mortality. We collected comprehensive medical information of healthy and sick newborns and their families, together with infant blood samples for proteomic analysis. MUNICH-PreTCl aims to identify mechanism-based biomarkers in infant health and disease to deliver more precise diagnostic and predictive information for disease prevention.

View Article and Find Full Text PDF